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We recently identified lamin A/C as a docking molecule for human histone deacetylase
2 (HDAC2) and showed involvement of HDAC2-lamin A/C complexes in the DNA
damage response. We further showed that lamin A/C-HDAC2 interaction is altered
in Hutchinson-Gilford Progeria syndrome and other progeroid laminopathies. Here, we
show that both inhibitors of lamin A maturation and small molecules inhibiting HDAC
activity affect lamin A/C interaction with HDAC2. While statins, which inhibit prelamin
A processing, reduce protein interaction, HDAC inhibitors strengthen protein binding.
Moreover, treatment with HDAC inhibitors restored the enfeebled lamin A/C-HDAC2
interaction observed in HGPS cells. Based on these results, we propose that prelamin
A levels as well as HDAC2 activation status might influence the extent of HDAC2
recruitment to the lamin A/C-containing platform and contribute to modulate HDAC2
activity. Our study links prelamin A processing to HDAC2 regulation and provides
new insights into the effect of statins and histone deacetylase inhibitors on lamin A/C
functionality in normal and progeroid cells.
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INTRODUCTION
Histone-modifying enzymes are fine regulators of chromatin remodeling and include histone
methyl-transferases and demethylases, histone acetyltransferases and deacetylases, histone kinases
and ubiquitin ligases. Histone deacetylases (HDACs), which counteract histone acetylation favoring
a repressive chromatin status, belong to three major classes and a fourth class that only includes
HDAC11 (Seto and Yoshida, 2014). Class I HDACs, encompassing HDAC1, HDAC2, HDAC3,
and HDAC8, are ubiquitously expressed and are mainly localized within the nucleus, where they
deacetylate diverse histone residues to modulate transcription and other nuclear processes (Seto
and Yoshida, 2014). In particular, class I HDACs are involved in DNA damage signaling and it has
been reported that HDAC1 and -2 have a central role in preparing the chromatin for the activation
of DNA damage response (DDR) (Roos and Krumm, 2016). Furthermore, it has been demonstrated
that HDAC2 is involved in DDR through regulation of acetylation of H4K16 and H3K56
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(Miller et al., 2010). Class II HDACs (HDAC4-7, -9 and -10) are
expressed in a tissue-specific way and are mostly cytoplasmic,
some of them have been reported abundant also in nucleus
(HDAC6) (Seidel et al., 2015) and others translocate into
the nucleus upon stimulus-induced phosphorylation and are
exported to the cytoplasm upon binding to 14-3-3 protein
(Nishino et al., 2008; Di Giorgio et al., 2015). Class III
HDACs, known as sirtuins and including SIRT1-7, are located
in the nucleus or in the cytoplasm and also in mitochondria
and regulate acetylation of histones involved in transcriptional
regulation, metabolism and DDR (Roos and Krumm, 2016).
Furthermore, sirtuins are involved in aging pathways through
acetylation of histones or non-histone substrates (Saunders and
Verdin, 2007; Watroba and Szukiewicz, 2016). It has been
reported that lamin A/C regulates sirtuin activity and defects of
sirtuin anchorage (Cenni et al., 2014) and deacetylase function
were observed in progeroid laminopathies (Ghosh et al., 2013;
Liu and Zhou, 2013; Ghosh et al., 2015). Among progeroid
laminopathies, Hutchinson-Gilford Progeria syndrome (HGPS)
is a rare premature aging disease caused by mutations in
LMNA gene and, in most cases, production of a truncated
prelamin A form called progerin (Pellegrini et al., 2015). As in
most laminopathies, chromatin dynamics are altered in HGPS
and heterochromatin organization, histone methylation and
acetylation and DDR are severely affected (Columbaro et al.,
2005; Pellegrini et al., 2015; Evangelisti et al., 2016). We recently
found that lamin A/C interacts with HDAC2 and influences
HDAC2 recruitment to the p21 promoter, while lamin A/C-
HDAC2 interaction is reduced in HGPS cells (Mattioli et al.,
2018). We also observed that lamin A/C-HDAC2 interaction is
decreased during DDR and recovered at completion of DNA
repair in control human fibroblasts, whereas this modulation is
lost in HGPS cells (Mattioli et al., 2018). Furthermore, we showed
that lamin A/C interacts with HDAC2 to promote its deacetylase
activity and also this function is altered in HGPS cells (Mattioli
et al., 2018).
HDACs can be inhibited by an increasing number of
inhibitors, among which the best known is trichostatin A
(TSA), a potential therapeutic compound for cancer and many
other diseases (Seto and Yoshida, 2014). This is because TSA
(and by extension other HDAC inhibitors) may be used to
impair DDR and favor cell death, as in oncological applications,
or rather to activate transcription of repressed sequences,
as in muscular dystrophies (Bajanca and Vandel, 2017). We
previously demonstrated that the combined inhibition of HDAC
activity (with TSA) and prelamin A/progerin farnesylation
(with mevinolin) rescues aberrant chromatin organization and
transcriptional activity in cells from HGPS (Columbaro et al.,
2005). Those cells accumulate progerin, a truncated and
farnesylated form of the lamin A precursor (Mattioli et al.,
2018). The lamin A precursor, also known as prelamin A, is
produced as the main splicing product of the LMNA gene
and undergoes a complex post-translational processing leading
to lamin A maturation. The C-terminal CSIM sequence of
prelamin A undergoes farnesylation, cleavage by the Zinc-
dependent metalloprotease Zmpste24 and carboxymethylation.
Thereafter, removal of the last 15 amino acids through a second
Zmpste24-mediated cleavage yields mature lamin A (Worman
and Michaelis, 2018). Statins inhibit the HMG-CoA reductase
activity, which is necessary for production of the farnesyl group
(Mattioli et al., 2008). As farnesylation is the first modification
of prelamin A and it is required for further post-translational
processing, statins cause accumulation of unprocessed, non-
farnesylated prelamin A in cells (Bikkul et al., 2018). Here
we show that HDAC inhibitors as well as inhibitors of lamin
A maturation modulate the interaction of lamin A/C with
HDAC2. In particular, while statins reduce, HDAC inhibitors
strengthen protein interaction. Importantly, TSA rescues lamin
A/C-HDAC2 interaction in HGPS cells. Based on these results,
we propose that prelamin A levels as well as HDAC2 activation
status influence the extent of HDAC2 recruitment to A-type
lamins and contribute to modulate HDAC2 activity. These results
increase our understanding of the effect of drugs on lamin-
dependent epigenetic mechanisms and support the hypothesis
that TSA could represent a therapeutic tool for HGPS.
MATERIALS AND METHODS
Cell Culture and Transfection
Skin fibroblast cultures were obtained from skin biopsies of
healthy subjects undergoing orthopedic surgery due to trauma
or laminopathic patients, following a written consent. HGPS
fibroblasts carrying heterozygous p.G608G LMNA mutation
were from two patients aged 3 and 5 years. All cell cultures
were from the BioLaM biobank. The experimental protocol
had been approved by the local ethical committee (Rizzoli
Orthopedic Institute Ethical Committee approval Prot. Gen.
0018250 – 2016) and followed EU rules. Cell cultures were
established and cultured in Dulbecco’s modified Eagle’s medium,
supplemented with 20% fetal bovine serum (FBS) from Gibco
Life Technology and antibiotic-anti-mycotic solution from
Sigma. HEK 293 and HeLa cells were cultured in Dulbecco’s
modified Eagle’s medium, supplemented with 10% FBS. The
HeLa LMNA knockout (LMNA−/−) cell lines were generated
using CRISPR-Cas9 mediated genome editing technology with
a guide RNA targeting the first exon of the LMNA gene (5′-
CCTTCGCATCACCGAGTCTGAAG-3′), as described before
(Robijns et al., Scientific Reports 2016; Houthaeve et al., ACS
Nano 2018). Constructs containing the Cas9 nuclease and
selection markers were obtained from Addgene (#48138 and
48139) and published protocols were followed (Ran et al., Nature
Protocols 2013). Control cells (LMNA+/+) underwent the same
treatment with a construct containing no guide RNA.
Plasmids
HEK293 cells were transfected with FLAG-tagged plasmids
containing: wild-type prelamin A, LA-WT, which undergoes
normal maturation; LA-C661M, which cannot be farnesylated;
LA-L647R, which is farnesylated but cannot undergo
endoproteolysis and delta50 construct that mimic HGPS
patient (Lattanzi et al., 2007). Transfection of HEK293 cells was
performed using Fugene 6 solution (Promega) according to the
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manufacturer’s instructions and cells were incubated for 24 h
after transfection.
Antibodies and Drugs
Antibodies employed were: anti-lamin A/C, goat polyclonal
[Santa Cruz, SC-6215, used at 1:100 dilution for WB and in situ
proximity ligation assay (PLA)]; anti lamin A/C (Novocastra,
used for IP); anti-prelamin A, goat polyclonal (Santa Cruz,
SC-6214, used 1:100 for WB and for PLA analysis); 1188-1
rabbit-polyclonal anti-prelamin A (non-farnesylated) (Diatheva
used 1:50 for IF); 1188-2 rabbit-polyclonal anti-prelamin A
(farnesylated) (Diatheva used 1:10 for IF); anti-HDAC2, rabbit
polyclonal (Abcam, AB16032, used 1:3000 for WB and 1:200
for PLA analysis); anti-HDAC2, mouse monoclonal (Santa Cruz,
SC-55541 used 1:100 for PLA analysis); anti-H4K16 acetylated,
rabbit polyclonal (Abcam used 1:4000 for WB and 1:200 for PLA
analysis); anti-H3K9 acetylated, rabbit polyclonal (Abcam, used
1:500 for WB and 1:200 for PLA); anti-Flag tag (Sigma, 1:3000
for WB); anti-53BP1 (for IF); anti-GAPDH (Millipore 1:5000
for WB).
The HDAC inhibitor TSA (Sigma) was applied 1.5 µM for
18 h to cell cultures to induce Class I/II HDAC inhibition.
MS-275 (entinostat), a synthetic benzamide inhibitor selective
for HDAC1-3, was applied 5 µM for 18 h. MC1568, a class
II HDAC/HDAC8 inhibitor (Panella et al., 2016) was applied
5 µM for 18 h. Mevinolin (Sigma) was added 25 µM to
human fibroblasts and 3 µM to HeLa cells for 18 h. N-acetyl-
S-farnesyl-L-cysteine methylester (AFCMe, from Alexis), a non-
peptidomimetic ZMPSTE24 inhibitor, was added (10 µM) to cell
cultures for 18 h to accumulate farnesylated prelamin A (Cenni
et al., 2011). Mevinolin causes non-farnesylated prelamin A
accumulation through inhibition of farnesyl production. AFCMe
is a non-peptidomimetic small molecule that impairs binding of
the prelamin A endoprotease Zmpste24, thus impairing cleavage
and maturation of farnesylated prelamin A (Mattioli et al., 2008).
The dosage of mevinolin and TSA for combined treatment was
previously reported (Columbaro et al., 2005). To induce oxidative
stress, 100 µM hydrogen peroxide (H2O2) was added to human
dermal fibroblast cultures for 4 h. Recovery was measured 48 h
after H2O2 removal (Mattioli et al., 2018).
In situ Proximity Ligation Assay
The PLA experiments were performed using kits from
Sigma-Aldrich: Duolink R© in situ Detection Reagents Orange
(DUO92007) according to manufacturer instructions. Briefly,
methanol-fixed samples were treated with 4% BSA in PBS
to saturate non-specific binding and incubated with primary
antibodies overnight at 4◦C. Thereafter, slides were incubated for
1 h at 37◦C with secondary probes diluted to final concentrations
of 1:5. Ligation solution was added to each sample and slides
were incubated in a humidity chamber for 30 min at 37◦C.
Later ligation solution was removed with wash buffer A and
amplification solution was added to each sample. Slides were
incubated in a humidity chamber for 100 min at 37◦C and then
washed with wash buffers. Duolink in situ mounting medium
with DAPI was added to the slides and samples were observed by a
Nikon Eclipse Ni fluorescence microscope equipped with a digital
CCD camera and NIS Elements AR 4.3 software. Quantitative
analysis of PLA results was performed using Duolink Image Tool
software (Sigma) by counting 200 nuclei per sample.
Immunofluorescence Analysis
Cells grown on coverslips were fixed with absolute methanol
at −20◦C for 7 min. After saturation of non-specific binding
with PBS containing 4% BSA, coverslips were incubated with
primary antibodies overnight at 4◦C or 1 h, and revealed with
FITC or TRIC-conjugated secondary antibodies diluted 1:100
(incubated for 1 h at RT). Samples were mounted with an anti-
fade reagent (Molecular Probes, ThermoFisher) and observed
with a Nikon Eclipse Ni epifluorescence microscope. The images
captured with NIS- Elements 4.3 AR software were processed
using Photoshop CS.
Immunoblotting and
Immunoprecipitation
For Western blot analysis, human fibroblasts were lysed in a
buffer containing: 20 mM TRIS–HCl (pH = 7.5), 1% SDS,
1 mM Na3VO4, 1 mM PMSF, 5% beta-mercaptoethanol and
protease inhibitors. After sonication centrifugation and protein
quantification by Bradford method, proteins were subjected
to SDS gradient gel (5–20%) electrophoresis and transferred
to nitrocellulose membrane overnight at 4◦C. Incubation
with primary and secondary antibodies was performed and
immunoblotted bands were revealed by Invitrogen ECL detection
system.
For Immunoprecipitation experiments (IP) transfected
HEK293 cells or HeLa cells were lysed in high detergent-IP
buffer containing: 50 mM TRIS–HCl (pH = 8), 250 mM
NaCl, 0.1% SDS, 1% NP-40, 1 mM PMSF, and protease and
phosphatase inhibitors. For each samples 700 µg of lysate were
incubated over-night with 1 µg of anti-FLAG tag from Sigma
or 12 µl of anti-lamin A/C form Novocastra or non-specific
immunoglobulins form Santa Cruz Biotechnology as a negative
control. After the addition of 30 µl of protein A/G (Santa Cruz
Biotechnology) for 60 min at 4◦C, the immunoprecipitated
proteins were washed three times in IP buffer. Later the samples
were added to Laemmli’s buffer, boiled and subjected to western
blot analysis. The intensity of bands was measured using a
BioRad GS800 Densitometer.
Statistical Analysis
Graphs in each panel represent mean values from at least
three independent experiments +/− standard error. Statistically
significant differences (p< 0.05) are calculated by Student’s t-test.
RESULTS
Modulation of Lamin A/C-HDAC2
Interaction by Statins
We first tested the effect of mevinolin, a drug affecting
prelamin A processing, on the interaction between HDAC2
and lamin A/C using an antibody that recognizes all forms
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FIGURE 1 | Modulation of lamin A/C-HDAC2 interaction by statins. (A) Co-immunoprecipitation of lamin A/C and HDAC2 in the presence or absence of mevinolin as
indicated in the legend. A representative western blot is shown. Molecular weight markers are indicated in kDa. Densitometric analysis of immunoprecipitated
HDAC2 bands is reported in the graph. Statistical significance (p < 0.01) is indicated. (B) PLA of lamin A/C and HDAC2 or prelamin A and HDAC2 in human dermal
fibroblasts left untreated (NT) or treated with mevinolin (Mevinolin). Nuclei are counterstained with DAPI. Quantitative analysis of PLA signals (red dots) is reported in
the graphs. Statistical significance (p < 0.05) is indicated.
of A-type lamins including the precursors. To this end, we
performed co-immunoprecipitation experiments in cells treated
with mevinolin that, as all statins, impairs HMG-CoA reductase
activity and farnesyl production inducing non-farnesylated
prelamin A accumulation (Mattioli et al., 2008; Lattanzi et al.,
2014). Moreover, we measured lamin A/C-HDAC2 complexes
in fibroblasts that had accumulated farnesylated prelamin A
due to AFCMe treatment (Mattioli et al., 2008; Lattanzi
et al., 2014). Lamin A/C-HDAC2 complexes were detected
in untreated cells, whereas a lower amount of HDAC2 co-
immunoprecipitated in mevinolin treated cells (Figure 1A). PLA
confirmed reduced lamin A/C-HDAC2 interplay in mevinolin-
treated skin fibroblasts (Figure 1B). However, the interaction
of lamin A/C with HDAC2 in cells that had accumulated
farnesylated prelamin A was comparable to that observed in
untreated cells (Supplementary Figure S1). Thus, mevinolin
reduces lamin A/C affinity for HDAC2. Based on these data,
we suspected that accumulation of non-farnesylated prelamin A
could reduce lamin A/C-HDAC2 interaction.
Low Affinity of Non-farnesylated
Prelamin A for HDAC2 Interaction
As a first step towards the understanding of mevinolin effects
on lamin A/C-HDAC2 interaction, we transfected FLAG-tagged
lamin A or unprocessable prelamin A mutants (Figure 2A)
in human HEK293 cells and co-immunoprecipitated HDAC2
using a FLAG-directed antibody. Both prelamin A forms
(LA-C661M, non-farnesylated prelamin A and LA-L647R,
farnesylated prelamin A) and mature lamin A co-precipitated
HDAC2 (Figure 2B). However, non-farnesylated prelamin A
showed low affinity for HDAC2 (Figure 2B). Also progerin, the
prelamin A form found in HGPS, showed reduced interaction
with HDAC2 relative to other LMNA products (Figure 2B). Since
progerin is a truncated and farnesylated prelamin A form, our
observation suggested that the amino acid sequence deleted in
progerin could be involved in HDAC2 interaction.
Of note, in cells expressing non-farnesylated prelamin A
or progerin, acetylation of the HDAC2 substrate H4K16 was
slightly, but significantly increased (Figure 2C), supporting
previous observations linking lamin A/C-HDAC2 interaction to
enzyme activity (Mattioli et al., 2018). Moreover, we observed
that in cells where LMNA expression had been knocked-out by
CRISPR/Cas9 technology, mevinolin treatment did not affect
acetylation of H4K16 (Figure 2D). This result strongly indicated
that mevinolin-induced changes of H4K16 acetylation levels are
due to accumulation of non-farnesylated prelamin A and altered
lamin A/C-HDAC2 interaction.
We previously reported that lamin A maturation is slowed
down and prelamin A is accumulated at the early stages of
DDR, while its processing rate is increased and precursors
almost undetectable upon DNA damage recovery (Lattanzi et al.,
2014). Here, we confirmed that diverse prelamin A forms were
accumulated at different stages during stress response. Increase of
non-farnesylated prelamin A was observed after 4 h of oxidative
stress, while this form of the lamin A precursor was undetectable
upon DNA damage recovery (Figure 2E). In cells subjected
to oxidative stress, we could also detect prelamin A-HDAC2
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FIGURE 2 | Low affinity of HDAC2 for non-farnesylated prelamin A. (A) Schematic representation of lamin A mutants used in these experiments. The mutation is
reported in boxes. The name of each plasmid (LA-WT, LA-C661M, LA-L647R), the tag (FLAG) and mutations (crossed amino acid replaced by the following) are
indicated; F, farnesyl residue. (B) Co-immunoprecipitation of FLAG-lamin A and endogenous HDAC2 in HEK293 cells expressing FLAG-tagged wild-type lamin A
(LA-WT), non-farnesylable prelamin A (LA-C661M), uncleavable farnesylated prelamin A (LA-L647R) and lamin A delta 50 encoding progerin (progerin). Quantitative
analysis of HDAC2 IP band normalized on immmoprecipitated FLAG was performed. Statistical significance is indicated by asterisks (∗∗p < 0.01; ∗p < 0.05).
(C) Western blot analysis of H4K16ac in human HEK293 cells expressing FLAG-tagged wild-type lamin A (LA-WT), non-farnesylable prelamin A (LA-C661M),
uncleavable farnesylated prelamin A (LA-L647R) and lamin A delta 50 encoding progerin (progerin). GAPDH bands are shown as loading control. Quantitative
analysis of HDAC2 IP band normalized on immmoprecipitated lamin A/C was performed. (D) Western blotting analysis of lamin A/C and H4K16ac in LMNA +/+ and
LMNA −/− in absence or presence of mevinolin. Densitometric analysis of H4K16ac bands is reported in the graph. GAPDH was used as a loading control.
(E) Immunofluorescence staining of non-farnesylated prelamin A and farnesylated prelamin A during oxidative stress-induced DDR. Nuclei from untreated human
fibroblasts (NT), cells after 4 h H2O2 treatment (H2O2) or after H2O2 treatment and 48 h recovery (RECOVERY) are shown. Quantitative analysis of mean
fluorescence intensity measured in 100 nuclei from each sample is shown in the graphs. Statistical significance (p < 0.01 or p < 0.05) is indicated. (F)
Immunofluorescence analysis of prelamin A and PLA of lamin A/C and HDAC2 in the same samples shown in (D). Nuclei are counterstained with DAPI. Quantitative
analysis of PLA signals is shown in the graph. Statistical significance (p < 0.01) is indicated.
complexes (Figure 2F). Moreover, an inverse correlation was
determined between levels of non-farnesylated prelamin A and
lamin A/C-HDAC2 interaction during DDR (Figure 2F). The
latter finding, suggested that prelamin A increase contributed to
the observed reduction of lamin A/C-HDAC2 interaction during
DDR (Mattioli et al., 2018).
Modulation of Lamin A/C –HDAC2
Interaction by HDAC Inhibitors
Then, we wished to test if modulation of HDAC activity by
HDAC inhibitors could affect lamin A/C–HDAC2 interaction.
To this purpose, we treated human dermal fibroblasts with
TSA, a well-known pan-HDAC inhibitor, MS-275, a class
I-selective HDAC inhibitor active against HDAC1, HDAC2,
and HDAC3, and MC1568 to be used as a negative control.
Unexpectedly, all treatments increased HDAC2 recruitment
by lamin A/C (Figure 3A). The increased interaction after
addition of TSA and MS-275 suggests that the catalytically
inactive conformation of the enzyme has a higher affinity
for lamin A/C (Figure 3A). On the other hand, the effect
observed with MC1568, inactive against HDAC2, could be
in part explained by indirect posttranslational modification of
HDAC2 elicited by the inhibitor. Indeed, HDAC2 has been
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FIGURE 3 | HDACs inhibitors influence lamin A/C-HDAC2 interaction. (A) PLA of lamin A/C and HDAC2 in human dermal fibroblasts left untreated (NT) or treated
with HDAC inhibitors TSA (TSA), MS-275 (MS275) or MC1568 (MC1568). PLA of lamin A/C and HDAC2 in cells subjected to HDAC2 knockdown (siRNA HDAC2) or
to a control siRNA (control siRNA) is shown in the right panel. HDAC2 was labeled by a specific antibody to show protein downregulation (HDAC2). Red dots, PLA
signals. Quantitative analysis of PLA signals is reported in the graph. (B) PLA of lamin A/C and H4K16ac in human fibroblasts left untreated or treated with MS-275.
Quantitative analysis of total PLA signals and percentage of signals at the periphery with respect to total signals are indicated in the graphs. (C) PLA of HDAC2 and
H4K16ac in fibroblasts left untreated or treated with MS 275. Quantitative analysis of PLA signals is reported in the graph. (D) Cartoon representing a working
hypothesis based on the assumption that active HDAC2 (yellow), upon inhibition by MS-275, changes its conformation (pink) thus increasing its affinity for lamin A/C.
Lamin A/C binds H4K16ac and inactive HDAC2, lamin A/C binding activates HDAC2 and de-acetylated H4K16 is released. Nuclei in (A–C) are counterstained with
DAPI. Statistical significance (p < 0.05 or p < 0.01) is indicated.
reported to be acetylated by the histone acetyltransferase PCAF
and deacetylated by HDAC5 (Eom et al., 2014). MC1568,
an HDAC5 inhibitor, could increase HDAC2 acetylation level
thus favoring lamin A/C interaction. It has been demonstrated
that also TSA treatment increases HDAC2 acetylation (Eom
et al., 2014). Based on these considerations, we speculate that
HDAC2 acetylation could itself increase the interaction of
lamin A/C with the enzyme. Treatment of fibroblasts with the
HDAC2 inhibitor MS-275 also increased lamin A/C-H4K16Ac
interaction, as determined by PLA (Figure 3B), possibly due
to increased availability of the acetylated histone. Lamin A/C-
H4K16Ac complexes were clearly detectable at the nuclear rim
in more than 40% of quantified nuclei (Figure 3B), while, as
expected, HDAC2-H4K16Ac binding decreased after MS-275
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treatment (Figure 3C). In this scenario, we propose a model of
lamin A/C-HDAC2 interaction based on the hypothesis that, in
the presence of HDAC inhibitors, lamina A/C recruits histone
substrates of HDAC2 (including H4K16Ac) to the inactive
enzyme and favors its activity (Figure 3D).
Rescue of Lamin A/C-HDAC2 Interaction
in HGPS Cells by HDAC Inhibitors
We previously reported that a combination of mevinolin
and TSA is able to rescue several hallmarks of the HGPS
cellular phenotype including peripheral heterochromatin loss,
reduced transcriptional activity and altered nuclear morphology
(Columbaro et al., 2005). The same drug combination was also
effective in A type Mandibuloacral dysplasia cells (Camozzi et al.,
2012). We recently discovered a reduced lamin A/C-HDAC2
interaction in HGPS cells (Mattioli et al., 2018). Here, we wanted
to test TSA in HGPS fibroblasts and evaluate HDAC2-lamin
A/C interaction and H4K16 acetylation levels. Increased lamin
A/C-HDAC2 interaction was determined upon TSA treatment
both in control and HGPS fibroblasts (Figure 4A). Moreover,
the combined treatment with mevinolin and TSA also increased
lamin A/C-HDAC2 interaction both in control and HGPS
cells (Figure 4A). Of note, while in control fibroblasts TSA
induced histone acetylation, as expected, this was not the case in
HGPS (Figure 4B). In fact, while increased H3K9 and H4K16
acetylation were found in untreated HGPS cells, as reported
before (Mattioli et al., 2018), H4K16ac and H3K9ac levels did
not change after TSA treatment (Figure 4B). Moreover, we
noticed that, while progerin (Figure 4B) or HDAC2 levels were
not affected by TSA, this drug treatment reduced progerin–
HDAC2 interaction (Figure 4C). This effect could contribute to
rescue lamin A/C binding to HDAC2 in HGPS cells (Mattioli
et al., 2018). This surprising result prompted us to test the effect
of MS-275 that specifically inhibits class I HDACs including
HDAC1 and HDAC2. MS-275 treatment also increased lamin
A/C-HDAC2 interaction (Figure 3A), but also HDAC2 substrates
H3K9 and H4K16 acetylation levels (Figure 4D). As a whole,
these results indicate TSA as a good pharmacological tool for
progeria cells as rescue of HDAC2-lamin A/C interaction occurs
in TSA-treated HGPS cells, while excess histone acetylation is
avoided.
DISCUSSION
In this paper, we show that mevinolin and HDAC inhibitors
affect lamin A/C-HDAC2 interaction in human cells. Statins
are known inhibitors of prelamin A processing leading to
accumulation of non- farnesylated prelamin A (Columbaro
et al., 2005). Their effect in HGPS (Columbaro et al., 2005;
Varela et al., 2008; Harhouri et al., 2018) and that of other
drugs able to accumulate non-farnesylated prelamin A (Gabriel
et al., 2017) has been widely tested and shown to improve
the cellular phenotype as well as disease symptoms in animal
models. Some beneficial effect of inhibitors of prelamin A
farnesylation have been also reported in clinical trials in HGPS
patients (Gordon et al., 2018). However, the molecular target(s)
downstream of non-farnesylated prelamin A in HGPS cells
had been elusive. Here, we identify the lamin A/C-HDAC2
containing platform as a target of statins both in control and
progeria cells and show that statins weaken lamin A/C-HDAC2
interaction. Importantly, the effect on the lamin A/C containing
platform elicits acetylation of HDAC2 substrate H4K16, which
supports the view that loss of lamin A/C interaction reduces
HDAC2 activity (Mattioli et al., 2018). Although mevinolin
is known to impair farnesylation of several molecules and
cholesterol synthesis, the observation that this drug treatment
does not elicit H4K16 acetylation in cells devoid of lamin A/C
hints in favor of a direct role of prelamin A accumulation in
mevinolin effect on HDAC2. Further, data obtained in cells
overexpressing prelamin A forms, support the hypothesis that
prelamin A processing rate influences lamin A/C interaction
with HDAC2. In particular, non-farnesylated prelamin A, either
accumulated by mevinolin treatment or by expression of a non-
farnesylable prelamin A mutant, showed reduced affinity for
HDAC2 and its substrate H4K16ac. Hence, in the presence of
non-farnesylated prelamin A, reduced formation of lamin A/C-
HDAC2 complexes is observed. However, farnesylated prelamin
A accumulation does not interfere with lamin A/C-HDAC2
interaction. These findings are also relevant to the understanding
of lamin A/C-HDAC2 interplay during DDR. In fact, we show
that non-farnesylated prelamin A is accumulated during DDR.
Thus, reduced formation of lamin A/C-HDAC2 complexes
in cells subjected to oxidative stress could be explained by
transient accumulation of the low affinity non-farnesylated form
of the lamin A precursor. Transient increase of prelamin A
levels during DDR had been previously reported and we had
further shown that only cells from centenarians retain low
amounts of farnesylated prelamin A at recovery from DNA
damage, while prelamin A is almost undetectable in human
fibroblasts under basal conditions (Lattanzi et al., 2014). In that
study, we showed that 53BP1 import in nuclei upon oxidative
stress induction was favored by prelamin A accumulation
(Lattanzi et al., 2014). Data here reported, by showing that
non-farnesylated prelamin A contributes to reduced HDAC2
activity and histone deacetylation, add further knowledge to
the biological significance of transient prelamin A accumulation
during DDR.
The different affinity of prelamin A forms for HDAC2 could
play a role also in the pathogenesis of progeroid laminopathies,
where accumulation of prelamin A occurs. In agreement with
this hypothesis, we show that lamin A/C-HDAC2 binding is
severely affected in cells from HGPS and other progeroid
laminopathy patients [this paper and (Mattioli et al., 2018)].
In fact, the presence of progerin severely reduces lamin A/C-
HDAC2 interaction. However, since progerin is a farnesylated
form of prelamin A, and we show farnesylated prelamin A not
to alter HDAC2 binding, we conclude that the 50 amino acids
deleted in progerin are necessary to stabilize HDAC2-lamin A/C
complexes. On the other hand, we previously showed that both
non-farnesylated and farnesylated prelamin A are recovered in
MADA cells (Camozzi et al., 2012). Thus, accumulation of non-
farnesylated prelamin A could in part explain reduced lamin
A/C-HDAC2 complexes in MADA (Mattioli et al., 2018).
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FIGURE 4 | Rescue of lamin A/C-HDAC2 interaction in HGPS by TSA. (A) PLA of lamin A/C and HDAC2 in human dermal fibroblasts left untreated (NT), treated with
TSA (TSA) or a combination of TSA and mevinolin (TSA + mevinolin). Quantitative analysis of PLA signals is reported in the graph. (B) Western blotting analysis of
lamin A/C, H4K16ac and H3K9ac in control and HGPS fibroblasts left untreated or treated with TSA. GAPDH was used as a loading control. Densitometric analysis
is reported in the graph. (C) PLA of progerin and HDAC2 in human dermal fibroblasts left untreated or treated with TSA. Quantitative analysis of PLA signals is
reported in the graph. (D) Western blotting analysis of H4K16ac and H3K9ac in control and HGPS fibroblasts left untreated or treated with MS-275. GAPDH was
used as a loading control. Densitometric analysis is reported in the graph. Nuclei in (A,C) are counterstained with DAPI. Statistical significance (p < 0.01) is indicated.
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In this paper, we show that lamin A/C-HDAC2 interaction
can be also modulated by HDAC inhibitors. Strengthening of
lamin A/C-HDAC2 binding by different HDAC inhibitors could
be explained by conformational modifications of HDAC2 able to
favor its interaction with lamin A/C. In particular, treatment with
the HDAC1/2 inhibitor MS-275 was able to reduce the binding
between HDAC2 and its substrate H4K16ac and increased lamin
A/C- H4K16ac interaction, suggesting that lamin A/C could
have higher affinity for the inactive enzyme. An hypothesis
based on the assumption that lamin A/C targets acetylated
H4K16 to HDAC2 and favors histone deacetylation is depicted
in Figure 3D.
Further, our results support the hypothesis that the acetylation
status of HDAC2 favors its binding with lamin A/C. In
fact both TSA and the class II inhibitor MC1568, which
trigger HDAC2 acetylation (Eom et al., 2014), increased
lamin A/C-HDAC2 interaction. Since phosphomimetic or non-
phosphorylable HDAC2 serine 394 mutants showed the same
affinity for lamin A binding as the unmodified enzyme (Mattioli
et al., 2018), we conclude that HDAC2 acetylation rather
than phosphorylation, might regulate its binding properties
relative to A type lamins. We suggest that lamin A/C
preferentially recruits the inactive acetylated enzyme to trigger
its activation. The finding that HDAC2 acetylation precedes
HDAC2 phosphorylation on serine 394 supports this hypothesis
(Eom and Kook, 2015). However, given the effect observed
using diverse deacetylase inhibitors, we cannot rule out the
possibility that even lamin A/C acetylation status could
influence its binding to HDAC2. This aspect deserves further
investigation.
Epigenetic changes and repeated oxidative stress induce
the aging process (Guillaumet-Adkins et al., 2017). Indeed, a
constitutively acetylated status of H4K16 induces a shortening
of lifespan (Dang et al., 2009). We recently described a
protein platform including HDAC2, H4K16ac, and lamin A/C,
able to regulate epigenetic modifications of chromatin during
DNA repair. Defects of lamin A/C within this platform could
contribute to a defective DDR and induce cellular senescence.
A reduced binding between lamin A/C and HDAC2 was in fact
observed in HGPS cells (Mattioli et al., 2018). Furthermore,
HGPS cells showed defective modulation of HDAC2 substrates,
H3K9ac and H4K16ac, during oxidative stress response (Mattioli
et al., 2018). In this paper, we show that TSA treatment of
HGPS cells restores HDAC2-lamin A/C interaction and the
effect is also obtained by combining mevinolin and TSA. These
findings can in part explain the beneficial effect observed
in HGPS fibroblasts following TSA treatment in combination
with mevinolin (Columbaro et al., 2005). Importantly, TSA
treatment elicited far different effects on histone acetylation
in HGPS cells with respect to controls. In fact, very low, not
statistically significant, increase of H4K16 and H3K9 acetylation
was observed in HGPS cells subjected to TSA. This result
could be explained by rescue of HDAC2 function in HGPS
cells, due to recovery of HDAC2-lamin A/C interaction after
TSA treatment. Considering that TSA binding to HDACs is a
reversible process (Seto and Yoshida, 2014), rescue of HDAC2-
lamin A/C binding could overcome the inhibitory effect of
TSA and help restoring enzyme activity. This is particularly
relevant for cellular senescence, as we recently showed that
lamin A/C-HDAC2 interaction is related to expression of
the senescence marker p21. In fact, not only loss of lamin
A/C interaction, but also reduced binding of HDAC2 to
the p21 promoter occurs in HGPS cells (Mattioli et al.,
2018).
Thus, modulation of lamin A/C-HDAC2 interaction by
HDACs inhibitors suggests a potential therapeutic approach in
progeroid laminopathies, which warrants further investigation.
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